{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:23:08Z","timestamp":1762608188539,"version":"3.40.5"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>In the phase III CASTOR trial, daratumumab, bortezomib and dexamethasone (D\u2010Vd) significantly extended progression\u2010free survival compared with bortezomib and dexamethasone (Vd) alone in patients with relapsed\/refractory multiple myeloma (RRMM). Here, we present patient\u2010reported outcomes (PROs) from the CASTOR trial. PROs were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30\u2010item (EORTC QLQ\u2010C30) and the EuroQol 5\u2010dimensional descriptive system questionnaire. Treatment effects through Cycle 8 were measured by a repeated measures mixed\u2010effects model. After Cycle 8, PROs were only collected for patients in the D\u2010Vd group who continued on daratumumab monotherapy. Compliance rates for PRO assessments were high and similar between treatment groups. Mean changes from baseline were generally similar between treatment groups for EORTC QLQ\u2010C30 global health status (GHS), functioning and symptoms, and did not exceed 10 points for either treatment group. Subgroup analyses were consistent with the results observed in the overall population. There was no change in patients' health\u2010related quality of life for the first eight cycles of therapy; thereafter, patients treated with daratumumab over the long\u2010term reported improvements in GHS and pain. These results complement the significant clinical benefits observed with D\u2010Vd in patients with RRMM and support its use in this patient population.<\/jats:p>","DOI":"10.1111\/bjh.17321","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T11:56:22Z","timestamp":1612871782000},"page":"561-569","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Health\u2010related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial"],"prefix":"10.1111","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"first","affiliation":[{"name":"Santa Casa Medical School S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[{"name":"Ankara University Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[{"name":"University Medical Center of Hamburg\u2010Eppendorf Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute Emory University Atlanta GA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamas","family":"Masszi","sequence":"additional","affiliation":[{"name":"Semmelweis University Budapest Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[{"name":"Charles University and General Hospital Prague Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Munder","sequence":"additional","affiliation":[{"name":"Third Department of Medicine University Medical Center of the Johannes Gutenberg\u2010University Mainz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda\u2010Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"University Hospital of Salamanca\/IBSAL Salamanca Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomer M.","family":"Mark","sequence":"additional","affiliation":[{"name":"University of Colorado\u2010Anschutz Medical Campus Aurora CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Qi","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Qin","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Fastenau","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Raritan NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[{"name":"Malignant Haematology and Stem Cell Transplantation Service Alfred Health\u2010Monash University Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute Rotterdam the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Garvin","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Renaud","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Raritan NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine S.","family":"Gries","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Raritan NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12790"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2644-6"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12012"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222299"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14058"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.120121"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15248"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1747066"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01788.x"},{"issue":"14","key":"e_1_2_8_11_1","first-page":"220","article-title":"The clinical course of multiple myeloma in the era of novel agents: a retrospective, single\u2010center, real\u2010world study","volume":"1","author":"Szabo AG","year":"2019","journal-title":"Clin Hematol Int"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1991-4"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0181-0"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02392-6"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.7934"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3474.3474"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501351"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4531.4531"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23693"},{"key":"e_1_2_8_23_1","unstructured":"Janssen Biotech Inc.DARZALEX\u00ae(daratumumab) injection for intravenous use [prescribing information]. Horsham PA 2019."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194118"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01665.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-5-70"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1613886"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.847933"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.024"},{"key":"e_1_2_8_33_1","unstructured":"ScottNW FayersPM AaronsonNK BottomleyA deGraeffA GroenvoldM et al.EORTC QLQ\u2010C30 reference values. EORTC Quality of Life Group;2008[cited July 2008]. Available from:https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/reference_values_manual2008.pdf."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6205"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17321","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.17321","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T09:09:20Z","timestamp":1693559360000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.17321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1111\/bjh.17321"],"URL":"https:\/\/doi.org\/10.1111\/bjh.17321","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"2020-10-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}